[시장보고서]세포 및 유전자 치료 임상시험 서비스 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

세포 및 유전자 치료 임상시험 서비스 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

Global Cell & Gene Therapy Clinical Trial Services Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

상품코드 : 1489278

리서치사 : Value Market Research

발행일 : 2024년 05월

페이지 정보 : 영문 222 Pages

라이선스 & 가격 (부가세 별도)

US $ 3,920

￦ 5,816,000

PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

US $ 4,730

￦ 7,017,000

PDF & Excel (10-user License)

PDF 및 Excel 보고서를 동일 기업 내 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

US $ 7,430

￦ 11,023,000

PDF & Excel (Corporate User License)

PDF 및 Excel 보고서를 동일 기업 내 모든 사용자가 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세포 및 유전자 치료 임상시험 서비스 시장의 세계 수요는 2023년 45억 3,000만 달러에서 2032년 거의 118억 9,000만 달러의 시장 규모에 도달할 것으로 추정되며, 2024-2032년 기간 동안 11.32%의 CAGR을 기록할 것으로 예상됩니다.

세포 및 유전자 치료 임상시험 서비스는 유전자 및 세포를 변형시켜 질병을 관리하고 예방하는 혁신적인 치료제의 개발 및 시험을 지원합니다. 이러한 서비스에는 환자 모집, 규제 준수, 치료제 제조, 임상시험 관리 등 다양한 활동이 포함됩니다. 이러한 서비스는 임상시험이 안전하고 윤리적이고 효율적으로 수행되도록 보장함으로써 과학적 돌파구를 실행 가능한 치료법으로 전환하는 데 있어 매우 중요합니다. 이러한 서비스 제공자들은 연구자, 제약회사 및 의료 기관과 긴밀히 협력하여 세포 및 유전자 치료 시험의 복잡한 상황을 극복하고 궁극적으로 생명을 구할 수 있는 새로운 치료법을 시장에 출시하는 것을 목표로 하고 있습니다.

시장 역학

연구개발 활동의 급증과 혁신적인 치료법에 대한 수요 증가로 인해 세포 및 유전자 치료 임상시험 서비스에 대한 수요가 급증하고 있습니다. 기업과 학계는 이러한 획기적인 치료법 개발에 막대한 자금을 투자하고 있으며, 이는 전 세계적으로 임상시험이 급증하고 있는 추세입니다. 유전성 질환과 만성 질환의 급증은 효과적인 세포 및 유전자 치료의 시급성을 더욱 강조하고 있으며, 이를 뒷받침할 수 있는 종합적인 임상시험 서비스의 필요성을 더욱 강조하고 있습니다. 세포 및 유전자 치료의 헬스케어 혁신 가능성은 지속되고 있으며, 이는 임상 연구에 대한 지속적인 관심과 투자를 촉진하고 있습니다. 세포 및 유전자 치료 임상시험 서비스를 추진하기 위해서는 업계 이해관계자, 규제 기관 및 연구 기관의 협력이 필수적입니다. 그러나 엄격한 규제 요건과 복잡한 윤리적 고려사항은 향후 몇 년 동안 세포 및 유전자 치료 임상시험 서비스 시장의 성장에 영향을 미칠 수 있습니다.

이 조사 보고서는 Porter's Five Forces 모델, 시장 매력도 분석, 밸류체인 분석을 다루고 있습니다. 이러한 도구는 산업 구조를 명확하게 파악하고 세계 수준에서 경쟁의 매력을 평가하는 데 도움이 됩니다. 또한, 이 도구는 세포 및 유전자 치료 임상시험 서비스 세계 시장에서 각 부문을 포괄적으로 평가할 수 있도록 도와줍니다. 세포 및 유전자 치료 임상시험 서비스 산업의 성장과 동향은 이 조사에 대한 전체적인 접근 방식을 제공합니다.

지역 분석

이 섹션에서는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카의 세포 및 유전자 치료 임상시험 서비스 시장의 현재 및 미래 수요를 파악할 수 있는 지역별 전망을 다룹니다. 또한, 이 보고서는 모든 주요 지역의 개별 응용 부문의 수요, 추정 및 예측에 초점을 맞추고 있습니다.

요청이 있으시면 저희에게 연락 주시기 바랍니다. 당사의 조사팀은 고객의 요구에 따라 맞춤형 보고서를 제공할 수 있습니다.

지역별 전망
소개
북미 매출 분석
- 개요, 실적과 예측
- 북미 : 부문별
- 북미 : 국가별
- 미국
- 캐나다
- 멕시코
유럽 매출 분석
- 개요, 실적과 예측
- 유럽 : 부문별
- 유럽 : 국가별
- 영국
- 프랑스
- 독일
- 이탈리아
- 러시아
- 기타 유럽
아시아태평양 매출 분석
- 개요, 실적과 예측
- 아시아태평양 : 부문별
- 아시아태평양 : 국가별
- 중국
- 인도
- 일본
- 한국
- 호주
- 동남아시아
- 기타 아시아태평양
라틴아메리카 매출 분석
- 개요, 실적과 예측
- 라틴아메리카 : 부문별
- 라틴아메리카 : 국가별
- 브라질
- 아르헨티나
- 페루
- 칠레
- 기타 라틴아메리카
중동 및 아프리카 매출 분석
- 개요, 실적과 예측
- 중동 및 아프리카 : 부문별
- 중동 및 아프리카 : 국가별
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카

제11장 세포 및 유전자 치료 임상시험 서비스 기업 경쟁 상황

세포 및 유전자 치료 임상시험 서비스 시장 경쟁
파트너십/제휴/합의
인수합병
신제품 출시
기타 개발

제12장 기업 개요

상위 기업의 시장 점유율 분석
시장 집중도
Advarra
Charles River Laboratories International Inc.
Catalent Pharma
ICON PLC
IQVIA
Medpace Inc.
Novotech
Precision Medicine Group LLC
Parexel International
Syneos Health
Sharp Services LLC
Thermo Fisher Scientific Inc.
Worldwide Clinical Trials

ksm

영문 목차

영문목차

The global demand for Cell & Gene Therapy Clinical Trial Services Market is presumed to reach the market size of nearly USD 11.89 Billion by 2032 from USD 4.53 Billion in 2023 with a CAGR of 11.32% under the study period 2024-2032.

Cell and gene therapy clinical trial services support developing and testing innovative treatments that entail modifying genes or cells to manage or prevent diseases. These services encompass a variety of activities, including patient recruitment, regulatory compliance, manufacturing of therapeutic agents, and clinical trial management. They are crucial in translating scientific breakthroughs into viable therapies by ensuring trials are conducted safely, ethically, and efficiently. Providers of these services work closely with researchers, pharmaceutical companies, and healthcare institutions to navigate the complex landscape of cell and gene therapy trials, ultimately aiming to bring new, life-saving treatments to market.

MARKET DYNAMICS

The surge in research and development activities and the growing demand for innovative treatment options have propelled the demand for cell and gene therapy clinical trial services. Companies & academic institutions are spending heavily in advancing these groundbreaking therapies, leading to an upsurge in clinical trials worldwide. The spurring prevalence of genetic disorders & chronic diseases further underscores the urgency for effective cell and gene therapies, driving the need for comprehensive clinical trial services to support their development. The potential of cell & gene transformation to revolutionize healthcare persists, driving sustained interest and investment in clinical research. Collaborations between industry stakeholders, regulatory bodies, and research institutions are crucial for advancing cell and gene therapy clinical trial services. However, stringent regulatory requirements and complex ethical considerations may challenge the growth of the cell and gene therapy clinical trial services market in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Cell & Gene Therapy Clinical Trial Services. The growth and trends of Cell & Gene Therapy Clinical Trial Services industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Cell & Gene Therapy Clinical Trial Services market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Service

Clinical Trial Design & Planning
Supply & Logistics Services
Regulatory Affairs & Compliance
Data Management & Biostatistics
Site Management & Monitoring
Other Services

By Phase

Phase I
Phase II
Phase III
Phase IV

By Indication

Oncology
Hematology
Endocrine/metabolic Disorders
Infectious Diseases
Neurology
Cardiovascular Diseases
Musculoskeletal Disorders
Other indications

By Therapy Type

Gene Therapy
Cell Therapy
Gene Modified Cell Therapy

By End-Use

Pharmaceutical & Biotechnology Companies
Contract Research Organizations
Academic & Research Institutes
Other end-users

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cell & Gene Therapy Clinical Trial Services market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cell & Gene Therapy Clinical Trial Services market include Advarra, Charles River Laboratories International Inc., Catalent Pharma, ICON PLC, IQVIA, Medpace Inc., Novotech, Precision Medicine Group LLC, Parexel International, Syneos Health, Sharp Services LLC, Thermo Fisher Scientific Inc., Worldwide Clinical Trials. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. CELL & GENE THERAPY CLINICAL TRIAL SERVICES - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Service
- 3.7.2 Market Attractiveness Analysis By Phase
- 3.7.3 Market Attractiveness Analysis By Indication
- 3.7.4 Market Attractiveness Analysis By Therapy Type
- 3.7.5 Market Attractiveness Analysis By End-Use
- 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES MARKET ANALYSIS BY SERVICE

5.1. Overview By Service
5.2. Historical and Forecast Data
5.3. Analysis By Service
5.4. Clinical Trial Design & Planning Historic and Forecast Sales By Regions
5.5. Supply & Logistics Services Historic and Forecast Sales By Regions
5.6. Regulatory Affairs & Compliance Historic and Forecast Sales By Regions
5.7. Data Management & Biostatistics Historic and Forecast Sales By Regions
5.8. Site Management & Monitoring Historic and Forecast Sales By Regions
5.9. Other Services Historic and Forecast Sales By Regions

6. GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES MARKET ANALYSIS BY PHASE

6.1. Overview By Phase
6.2. Historical and Forecast Data
6.3. Analysis By Phase
6.4. Phase I Historic and Forecast Sales By Regions
6.5. Phase II Historic and Forecast Sales By Regions
6.6. Phase III Historic and Forecast Sales By Regions
6.7. Phase IV Historic and Forecast Sales By Regions

7. GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES MARKET ANALYSIS BY INDICATION

7.1. Overview By Indication
7.2. Historical and Forecast Data
7.3. Analysis By Indication
7.4. Oncology Historic and Forecast Sales By Regions
7.5. Hematology Historic and Forecast Sales By Regions
7.6. Endocrine/metabolic Disorders Historic and Forecast Sales By Regions
7.7. Infectious Diseases Historic and Forecast Sales By Regions
7.8. Neurology Historic and Forecast Sales By Regions
7.9. Cardiovascular Diseases Historic and Forecast Sales By Regions
7.10. Musculoskeletal Disorders Historic and Forecast Sales By Regions
7.11. Other indications Historic and Forecast Sales By Regions

8. GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES MARKET ANALYSIS BY THERAPY TYPE

8.1. Overview By Therapy Type
8.2. Historical and Forecast Data
8.3. Analysis By Therapy Type
8.4. Gene Therapy Historic and Forecast Sales By Regions
8.5. Cell Therapy Historic and Forecast Sales By Regions
8.6. Gene Modified Cell Therapy Historic and Forecast Sales By Regions

9. GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES MARKET ANALYSIS BY END-USE

9.1. Overview By End-Use
9.2. Historical and Forecast Data
9.3. Analysis By End-Use
9.4. Pharmaceutical & Biotechnology Companies Historic and Forecast Sales By Regions
9.5. Contract Research Organizations Historic and Forecast Sales By Regions
9.6. Academic & Research Institutes Historic and Forecast Sales By Regions
9.7. Other end-users Historic and Forecast Sales By Regions

10. GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1 Overview, Historic and Forecast Data Sales Analysis
- 10.3.2 North America By Segment Sales Analysis
- 10.3.3 North America By Country Sales Analysis
- 10.3.4 United States Sales Analysis
- 10.3.5 Canada Sales Analysis
- 10.3.6 Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1 Overview, Historic and Forecast Data Sales Analysis
- 10.4.2 Europe By Segment Sales Analysis
- 10.4.3 Europe By Country Sales Analysis
- 10.4.4 United Kingdom Sales Analysis
- 10.4.5 France Sales Analysis
- 10.4.6 Germany Sales Analysis
- 10.4.7 Italy Sales Analysis
- 10.4.8 Russia Sales Analysis
- 10.4.9 Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1 Overview, Historic and Forecast Data Sales Analysis
- 10.5.2 Asia Pacific By Segment Sales Analysis
- 10.5.3 Asia Pacific By Country Sales Analysis
- 10.5.4 China Sales Analysis
- 10.5.5 India Sales Analysis
- 10.5.6 Japan Sales Analysis
- 10.5.7 South Korea Sales Analysis
- 10.5.8 Australia Sales Analysis
- 10.5.9 South East Asia Sales Analysis
- 10.5.10 Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1 Overview, Historic and Forecast Data Sales Analysis
- 10.6.2 Latin America By Segment Sales Analysis
- 10.6.3 Latin America By Country Sales Analysis
- 10.6.4 Brazil Sales Analysis
- 10.6.5 Argentina Sales Analysis
- 10.6.6 Peru Sales Analysis
- 10.6.7 Chile Sales Analysis
- 10.6.8 Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1 Overview, Historic and Forecast Data Sales Analysis
- 10.7.2 Middle East & Africa By Segment Sales Analysis
- 10.7.3 Middle East & Africa By Country Sales Analysis
- 10.7.4 Saudi Arabia Sales Analysis
- 10.7.5 UAE Sales Analysis
- 10.7.6 Israel Sales Analysis
- 10.7.7 South Africa Sales Analysis
- 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE CELL & GENE THERAPY CLINICAL TRIAL SERVICES COMPANIES

11.1. Cell & Gene Therapy Clinical Trial Services Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12. COMPANY PROFILES OF CELL & GENE THERAPY CLINICAL TRIAL SERVICES INDUSTRY

12.1. Top Companies Market Share Analysis
12.2. Market Concentration Rate
12.3. Advarra
- 12.3.1 Company Overview
- 12.3.2 Company Revenue
- 12.3.3 Products
- 12.3.4 Recent Developments
12.4. Charles River Laboratories International Inc.
- 12.4.1 Company Overview
- 12.4.2 Company Revenue
- 12.4.3 Products
- 12.4.4 Recent Developments
12.5. Catalent Pharma
- 12.5.1 Company Overview
- 12.5.2 Company Revenue
- 12.5.3 Products
- 12.5.4 Recent Developments
12.6. ICON PLC
- 12.6.1 Company Overview
- 12.6.2 Company Revenue
- 12.6.3 Products
- 12.6.4 Recent Developments
12.7. IQVIA
- 12.7.1 Company Overview
- 12.7.2 Company Revenue
- 12.7.3 Products
- 12.7.4 Recent Developments
12.8. Medpace Inc.
- 12.8.1 Company Overview
- 12.8.2 Company Revenue
- 12.8.3 Products
- 12.8.4 Recent Developments
12.9. Novotech
- 12.9.1 Company Overview
- 12.9.2 Company Revenue
- 12.9.3 Products
- 12.9.4 Recent Developments
12.10. Precision Medicine Group LLC
- 12.10.1 Company Overview
- 12.10.2 Company Revenue
- 12.10.3 Products
- 12.10.4 Recent Developments
12.11. Parexel International
- 12.11.1 Company Overview
- 12.11.2 Company Revenue
- 12.11.3 Products
- 12.11.4 Recent Developments
12.12. Syneos Health
- 12.12.1 Company Overview
- 12.12.2 Company Revenue
- 12.12.3 Products
- 12.12.4 Recent Developments
12.13. Sharp Services LLC
- 12.13.1 Company Overview
- 12.13.2 Company Revenue
- 12.13.3 Products
- 12.13.4 Recent Developments
12.14. Thermo Fisher Scientific Inc.
- 12.14.1 Company Overview
- 12.14.2 Company Revenue
- 12.14.3 Products
- 12.14.4 Recent Developments
12.15. Worldwide Clinical Trials
- 12.15.1 Company Overview
- 12.15.2 Company Revenue
- 12.15.3 Products
- 12.15.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies